text:
Duloxetine
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Not to be confused with dapoxetine.
Duloxetine
Clinical data
Trade names
Cymbalta, many others[1]
AHFS/Drugs.com
Monograph
MedlinePlus
a604030
License data
EU EMA: by INN
US FDA: duloxetine
Pregnancy
category
AU: B3
US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
N06AX21 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)
CA: ℞-only
UK: POM (Prescription only)
US: ℞-only
Pharmacokinetic data
Bioavailability
~ 50% (32% to 80%)
Protein binding
~ 95%
Metabolism
Liver, two P450 isozymes, CYP2D6 and CYP1A2
Elimination half-life
12.1 hours
Excretion
70% in urine, 20% in feces
Identifiers
IUPAC name[show]
(+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine
CAS Number
116539-59-4
as HCl: 136434-34-9
PubChem CID
60835
IUPHAR/BPS
202
DrugBank
DB00476 Y
ChemSpider
54822 Y
UNII
O5TNM5N07U
as HCl: 9044SC542W
KEGG
D07880 Y
ChEBI
CHEBI:36795 Y
ChEMBL
CHEMBL1175 Y
PDB ligand
29E (PDBe, RCSB PDB)
ECHA InfoCard
100.129.057
Chemical and physical data
Formula
C18H19NOS
Molar mass
297.41456 g/mol
3D model (JSmol)
Interactive image
SMILES[show]
CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
InChI[show]
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1 Y
Key:ZEUITGRIYCTCEM-KRWDZBQOSA-N Y
Y (what is this?) (verify)
Duloxetine, sold under the brand name Cymbalta among others,[1] is a medication mostly used for major depressive disorder, generalized anxiety disorder, fibromyalgia and neuropathic pain.[2]
It is a thiophene derivative and a selective neurotransmitter reuptake inhibitor for serotonin, norepinephrine, and to a lesser degree dopamine. It belongs to a class of heterocyclic antidepressants known as serotonin–norepinephrine reuptake inhibitors (SNRIs).[3] It was originally made by Eli Lilly.
Contents
[hide]
1 Medical uses
1.1 Major depressive disorder
1.2 Generalized anxiety disorder
1.3 Diabetic peripheral neuropathy
1.4 Fibromyalgia and chronic pain
1.5 Stress urinary incontinence
2 Contraindications
3 Adverse effects
3.1 Discontinuation syndrome
3.2 Suicidality
3.3 Postmarketing reports
4 Pharmacology
4.1 Mechanism of action
4.2 Pharmacokinetics
5 History
6 References
7 External links
Medical uses[edit]
The main uses of duloxetine are in major depressive disorder, generalized anxiety disorder, neuropathic pain, chronic musculoskeletal pain, and fibromyalgia.[2][4][5][6]
Duloxetine is recommended as a first line agent for the treatment of chemotherapy-induced neuropathy by the American Society of Clinical Oncology,[7] as a first-line therapy for fibromyalgia in the presence of mood disorders by the German Interdisciplinary Association for Pain Therapy,[8] as a Grade B recommendation for the treatment of diabetic neuropathy by the American Association for Neurology[9] and as a level A recommendation in certain neuropathic states by the European Federation of Neurological Societies.[10]
A 2014 Cochrane review concluded that duloxetine is beneficial in the treatment of diabetic neuropathy and fibromyalgia but that more comparative studies with other medicines are needed.[11] The French medical journal Prescrire concluded that duloxetine is no better than other available agents and has a greater risk of side effects.[12] Thus they recommend against its general use.[12]
Major depressive disorder[edit]
Duloxetine was approved for the treatment of major depression in 2004. While duloxetine has demonstrated improvement in depression-related symptoms compared to placebo, comparisons of duloxetine to other antidepressant medications have been less successful. A 2012 Cochrane Review did not find greater efficacy of duloxetine compared to SSRIs and newer antidepressants. Additionally, the review found evidence that duloxetine has increased side effects and reduced tolerability compared to other antidepressants. It thus did not recommend duloxetine as a first line treatment for major depressive disorder, given the (then) high cost of duloxetine compared to inexpensive off-patent antidepressants and lack of increased efficacy.[13] Generic duloxetine became available in 2013.[14]
Generalized anxiety disorder[edit]
Duloxetine is more effective than placebo in the treatment of generalized anxiety disorder (GAD).[15] Major guidelines such as Maudsley Prescribing Guidelines,[16] and Canadian Psychiatric Association Guidelines[17] do not list duloxetine among the recommended treatment options. A review from the Annals of Internal Medicine lists duloxetine among the first line drug treatments, however, along with citalopram, escitalopram, sertraline, paroxetine, and venlafaxine.[18]
Diabetic peripheral neuropathy[edit]
Duloxetine was approved for the pain associated with diabetic peripheral neuropathy (DPN), based on the positive results of two clinical trials. The average daily pain was measured using an 11-point scale, and duloxetine treatment resulted in an additional 1–1.7 points decrease of pain as compared with placebo.[19][20][21] At least 50% pain relief was achieved in 40–45% of the duloxetine patients vs. 20–22% of placebo patients. Pain decreased by more than 90%, in 9–14% of duloxetine patients vs. 2–4% of placebo patients. Most of the response was achieved in the first two weeks on the medication. Duloxetine slightly increased the fasting serum glucose; this effect was deemed to be of "minimal clinical significance", however.[19]
The comparative efficacy of duloxetine and established pain-relief medications for DPN is unclear. A systematic review noted that tricyclic antidepressants (imipramine and amitriptyline), traditional anticonvulsants and opioids have better efficacy than duloxetine. Duloxetine, tricyclic antidepressants and anticonvulsants have similar tolerability while the opioids caused more side effects.[22] Another review in Prescrire International considered the moderate pain relief achieved with duloxetine to be clinically insignificant and the results of the clinical trials unconvincing. The reviewer saw no reason to prescribe duloxetine in practice.[23] The comparative data collected by reviewers in BMC Neurology indicated that amitriptyline, other tricyclic antidepressants and venlafaxine may be more effective. The authors noted that the evidence in favor of duloxetine is much more solid, however.[24] A Cochrane review concluded that the evidence in support of duloxetine's efficacy in treating painful diabetic neuropathy was adequate, and that further trials should focus on comparisons with other medications.[11]
Fibromyalgia and chronic pain[edit]
A review of duloxetine found that it reduced pain and fatigue, and improved physical and mental performance compared to placebo.[25]
The U.S. Food and Drug Administration (FDA) regulators approved the drug for the treatment of fibromyalgia in June 2008.[26]
It may be useful for chronic pain from osteoarthritis.[27][28]
On November 4, 2010, the U.S. Food and Drug Administration approved duloxetine to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.[29]
Stress urinary incontinence[edit]
Duloxetine failed to receive US approval for stress urinary incontinence amid concerns over liver toxicity and suicidal events; it was approved for this use in the UK, however, where it is recommended as an add-on medication in stress urinary incontinence instead of surgery.[30]
The safety and utility of duloxetine in the treatment of incontinence has been evaluated in a series of meta analyses and practice guidelines.
A 2017 meta-analysis found that harms are at least as great if not greater than the benefits.[31]
A 2013 meta-analysis concluded that duloxetine decreased incontinence episodes more than placebo with people about 56% more likely than placebo to experience a 50% decrease in episodes. Adverse effects were experienced by 83% of duloxetine-treated subjects and by 45% of placebo-treated subjects.[32]
A 2012 review and practice guideline published by the European Association of Urology concluded that the clinical trial data provides Grade 1a evidence that duloxetine improves but does not cure urinary incontinence, and that it causes a high rate of gastrointestinal side effects (mainly nausea and vomiting) leading to a high rate of treatment discontinuation.[33]
The National Institute for Clinical and Health Excellence recommends (as of September 2013) that duloxetine not be routinely offered as first line treatment, and that it only be offered as second line therapy in women wishing to avoid therapy. The guideline further states that women should be counseled regarding the drug's side effects.[34]
Contraindications[edit]
The following contraindications are listed by the manufacturer:[35]
Hypersensitivity: duloxetine is contraindicated in patients with a known hypersensitivity to duloxetine or any of the inactive ingredients.
Monoamine oxidase inhibitors (MAOIs): concomitant use in patients taking MAOIs is contraindicated.
Uncontrolled narrow-angle glaucoma: in clinical trials, Cymbalta use was associated with an increased risk of mydriasis (dilation of the pupil); therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma, in which mydriasis can cause sudden worsening.
Central nervous system (CNS) acting drugs: given the primary CNS effects of duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
Duloxetine and thioridazine should not be co-administered.
In addition, the FDA has reported on life-threatening drug interactions that may be possible when co-administered with triptans and other drugs acting on serotonin pathways leading to increased risk for serotonin syndrome.[36]
Adverse effects[edit]
Nausea, somnolence, insomnia, and dizziness are the main side effects, reported by about 10% to 20% of patients.[37]
In a trial for major depressive disorder (MDD), the most commonly reported treatment-emergent adverse events among duloxetine-treated patients were nausea (34.7%), dry mouth (22.7%), headache (20.0%) and dizziness (18.7%), and except for headache, these were reported significantly more often than in the placebo group.[38] In a long-term study of fibromyalgia patients receiving duloxetine, frequency and type of adverse effects was similar to that reported in the MDD above. Side effects tended to be mild-to-moderate, and tended to decrease in intensity over time.[39]
Sexual dysfunction is often a side effect of drugs that inhibit serotonin reuptake. Specifically, common side effects include difficulty becoming aroused, lack of interest in sex, and anorgasmia (trouble achieving orgasm). Loss of or decreased response to sexual stimuli and ejaculatory anhedonia are also possible. Frequency of treatment-emergent sexual dysfunction in long-term treatment has been found to be similar for duloxetine and SSRIs when compared in clinical trials,[40][41] while there is some evidence that duloxetine is associated with less sexual dysfunction than escitalopram when measured at 4 and 8 weeks of treatment.[41]
Discontinuation syndrome[edit]
Further information: SSRI discontinuation syndrome
During marketing of other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as brain zap electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. The withdrawal syndrome from duloxetine resembles the SSRI discontinuation syndrome.
When discontinuing treatment with duloxetine, the manufacturer recommends a gradual reduction in the dose, rather than abrupt cessation, whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
In placebo-controlled clinical trials of up to nine weeks' duration of patients with MDD, a systematic evaluation of discontinuation symptoms in patients taking duloxetine following abrupt discontinuation found the following symptoms occurring at a rate greater than or equal to 2% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare.[42]
Suicidality[edit]
The FDA requires all antidepressants, including duloxetine, to carry a black box warning stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on statistical analyses conducted by two independent groups of the FDA experts that found a 2-fold increase of the suicidal ideation and behavior in children and adolescents, and 1.5-fold increase of suicidality in the 18–24 age group.[43][44][45]
To obtain statistically significant results the FDA had to combine the results of 295 trials of 11 antidepressants for psychiatric indications. As suicidal ideation and behavior in clinical trials are rare, the results for any drug taken separately usually do not reach statistical significance.
In 2005 the United States FDA released a public health advisory noting that there had been 11 reports of suicide attempts and 3 reports of suicidality within the mostly middle-aged women participating in the open label extension trials of duloxetine for the treatment of stress urinary incontinence. The FDA described the potential role of confounding social stressors "unclear". The suicide attempt rate in the SUI study population (based on 9,400 patients) was calculated to be 400 per 100,000 person years. This rate is greater than the suicide attempt rate among middle-aged U.S. women that has been reported in published studies, i.e., 150 to 160 per 100,000 person years. In addition, one death from suicide was reported in a Cymbalta clinical pharmacology study in a healthy female volunteer without SUI. No increase in suicidality was reported in controlled trials of Cymbalta for depression or diabetic neuropathic pain.[46]
Postmarketing reports[edit]
Reported adverse events that were temporally correlated to duloxetine therapy include rash, reported rarely, and the following adverse events, reported very rarely: alanine aminotransferase increased, alkaline phosphatase increased, anaphylactic reaction, angioneurotic edema, aspartate aminotransferase increased, bilirubin increased, glaucoma, hepatotoxicity, hyponatremia, jaundice, orthostatic hypotension (especially at the initiation of treatment), Stevens–Johnson syndrome, syncope (especially at initiation of treatment), and urticaria.[47]
Pharmacology[edit]
Mechanism of action[edit]
Binding profile[48]
Receptor
Ki (nM)
SERT 0.8
NET 7.5
DAT 240
5-HT2A 504
5-HT2C 916
5-HT6 419
Duloxetine inhibits the reuptake of serotonin and norepinephrine (NE) in the central nervous system. Duloxetine increases dopamine (DA) specifically in the prefrontal cortex, where there are few DA reuptake pumps, via the inhibition of NE reuptake pumps (NET), which is believed to mediate reuptake of DA and NE.[49] Duloxetine has no significant affinity for dopaminergic, cholinergic, histaminergic, opioid, glutamate, and GABA reuptake transporters, however, and can therefore be considered to be a selective reuptake inhibitor at the 5-HT and NE transporters. Duloxetine undergoes extensive metabolism, but the major circulating metabolites do not contribute significantly to the pharmacologic activity.[50][51]
Major depressive disorder is believed to be due in part to an increase in pro-inflammatory cytokines within the central nervous system. Antidepressants including ones with a similar mechanism of action as duloxetine, i.e. serotonin metabolism inhibition, cause a decrease in proinflammatory cytokine activity and an increase in anti-inflammatory cytokines; this mechanism may apply to duloxetine in its effect on depression but research on cytokines specific to duloxetine therapy is lacking.[52]
The analgesic properties of duloxetine in the treatment of diabetic neuropathy and central pain syndromes such as fibromyalgia are believed to be due to sodium ion channel blockade.[53]
Pharmacokinetics[edit]
Absorption: Duloxetine is acid labile, and is formulated with enteric coating to prevent degradation in the stomach. Duloxetine has good oral bioavailability, averaging 50% after one 60 mg dose. There is an average 2-hour lag until absorption begins with maximum plasma concentrations occurring about 6 hours post dose. Food does not affect the Cmax of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours.[51]
Distribution: Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and α1-acid glycoprotein. Volume of distribution is 1640L.[54]
Metabolism: Duloxetine undergoes predominately hepatic metabolism via two cytochrome P450 isozymes, CYP2D6 and CYP1A2. Circulating metabolites are pharmacologically inactive.[54]
Elimination: Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state is usually achieved after 3 days. Only trace amounts (<1%) of unchanged duloxetine are present in the urine and most of the dose (approx. 70%) appears in the urine as metabolites of duloxetine with about 20% excreted in the feces.[54]
History[edit]
Cymbalta (duloxetine) 60mg
Duloxetine was created by Lilly researchers. David Robertson; David Wong, a co-discoverer of fluoxetine; and Joseph Krushinski are listed as inventors on the patent application filed in 1986 and granted in 1990.[55] The first publication on the discovery of the racemic form of duloxetine known as LY227942, was made in 1988.[56] The (+)-enantiomer of LY227942, assigned LY248686, was chosen for further studies, because it inhibited serotonin reuptake in rat synaptosomes to twice the degree of the (–)-enantiomer. This molecule was subsequently named duloxetine.[57]
In 2001, Lilly filed a New Drug Application (NDA) for duloxetine with the US Food and Drug Administration. In 2003, however, the FDA "recommended this application as not approvable from the manufacturing and control standpoint" because of "significant cGMP (current Good Manufacturing Practice) violations at the finished product manufacturing facility" of Eli Lilly in Indianapolis. Additionally, "potential liver toxicity" and QTc interval prolongation appeared as a concern. The FDA experts concluded that "duloxetine can cause hepatotoxicity in the form of transaminase elevations. It may also be a factor in causing more severe liver injury, but there are no cases in the NDA database that clearly demonstrate this. Use of duloxetine in the presence of ethanol may potentiate the deleterious effect of ethanol on the liver." The FDA also recommended "routine blood pressure monitoring" at the new highest recommended dose of 120 mg, "where 24% patients had one or more blood pressure readings of 140/90 vs. 9% of placebo patients."[58]
After the manufacturing issues were resolved, the liver toxicity warning included in the prescribing information, and the follow-up studies showed that duloxetine does not cause QTc interval prolongation, duloxetine was approved by the FDA for depression and diabetic neuropathy in 2004.[59] In 2007, Health Canada approved duloxetine for the treatment of depression and diabetic peripheral neuropathic pain.[60]
Duloxetine was approved for use of stress urinary incontinence (SUI) in the EU in 2004. In 2005, Lilly withdrew the duloxetine application for stress urinary incontinence (SUI) in the U.S., stating that discussions with the FDA indicated "the agency is not prepared at this time to grant approval ... based on the data package submitted." A year later Lilly abandoned the pursuit of this indication in the U.S. market.[61][62]
The FDA approved duloxetine for the treatment of generalized anxiety disorder in February 2007.[63]
Cymbalta generated sales of nearly $5 billion in 2012 with $4 billion of that in the U.S., but its patent protection terminated January 1, 2014. Lilly received a six-month extension beyond June 30, 2013 after testing for the treatment of depression in adolescents, which may produce $1.5 billion in added sales.[64][65] It was the most prescribed antidepressant in 2013–14.[66]
The first generic duloxetine was marketed by Dr. Reddy.[67]
References[edit]
^ Jump up to: a b Drugs.com International duloxetine brands Page accessed March 10, 2016
^ Jump up to: a b "Duloxetine". Monograph. The American Society of Health-System Pharmacists. Retrieved 2015-02-26.
Jump up ^ "MeSH Browser". meshb.nlm.nih.gov. Retrieved 2016-11-28.
Jump up ^ National Institute for Health and Clinical Excellence. Clinical guideline 96: Neuropathic pain – pharmacological management. London, 2010.
Jump up ^ Bril V, England J, Franklin GM, et al. (2011). "Evidence-based guideline: Treatment of painful diabetic neuropathy". Neurology. 76 (20): 1758–65. doi:10.1212/WNL.0b013e3182166ebe. PMC 3100130  . PMID 21482920.
Jump up ^ "Cymbalta (duloxetine hydrochloride) Delayed-Release Capsules for Oral Use" (PDF).
Jump up ^ Hershman DL, Lacchetti C, Dworkin RH, et al. (June 2014). "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline". J. Clin. Oncol. 32 (18): 1941–67. doi:10.1200/JCO.2013.54.0914. PMID 24733808.
Jump up ^ Sommer C, Häuser W, Alten R, et al. (June 2012). "[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]". Schmerz (in German). 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID 22760463.
Jump up ^ Bril V, England JD, Franklin GM, et al. (June 2011). "Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation". Muscle Nerve. 43 (6): 910–7. doi:10.1002/mus.22092. PMC 3100130  . PMID 21484835.
Jump up ^ Attal N, Cruccu G, Baron R, et al. (September 2010). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". Eur. J. Neurol. 17 (9): 1113–e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID 20402746.
^ Jump up to: a b Lunn MP, Hughes RA, Wiffen PJ (2014). "Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia". Cochrane Database Syst Rev. 1 (1): CD007115. doi:10.1002/14651858.CD007115.pub3. PMID 24385423.
^ Jump up to: a b "Towards better patient care: drugs to avoid in 2014". Prescrire International. 23 (150): 161–165. June 2014. PMID 25121155.
Jump up ^ Cipriani, A; Koesters, M; Furukawa, TA; Nosè, M; Purgato, M; Omori, IM; Trespidi, C; Barbui, C (Oct 17, 2012). "Duloxetine versus other anti-depressive agents for depression". The Cochrane Database of Systematic Reviews. 10: CD006533. doi:10.1002/14651858.cd006533.pub2. PMC 4169791  . PMID 23076926.
Jump up ^ Swiatek, Jeff (2013-10-13). "Loss of Cymbalta patent a major blow for Eli Lilly". Indianapolis Star. Retrieved 2015-02-27.
Jump up ^ Carter, NJ; McCormack, PL (2009). "Duloxetine: a review of its use in the treatment of generalized anxiety disorder". CNS Drugs. 23 (6): 523–41. doi:10.2165/00023210-200923060-00006. PMID 19480470.
Jump up ^ Kerwin, Robert; Taylor, David H.; Carol Paton (2007). Maudsley Prescribing Guidelines. Informa Healthcare. p. 254. ISBN 0-415-42416-X.
Jump up ^ Canadian Psychiatric, Association (July 2006). "Clinical practice guidelines. Management of anxiety disorders". Can J Psychiatry. 51 (8 Suppl 2): 52S–55S. PMID 16933543.
Jump up ^ Patel, G; Fancher, TL (Dec 3, 2013). "In the clinic. Generalized anxiety disorder". Annals of Internal Medicine. 159 (11): ITC6–1, ITC6–2, ITC6–3, ITC6–4, ITC6–5, ITC6–6, ITC6–7, ITC6–8, ITC6–9, ITC6–10, ITC6–11; quiz ITC6–12. doi:10.7326/0003-4819-159-11-201312030-01006. PMID 24297210.
^ Jump up to: a b Josefberg H (2004-09-03). "Application number 21-733. Medical review(s)" (PDF). FDA. Retrieved 2009-04-14. [dead link]
Jump up ^ Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S; Lu; Detke; Lee; Iyengar (July 2005). "Duloxetine vs. placebo in patients with painful diabetic neuropathy". Pain. 116 (1–2): 109–18. doi:10.1016/j.pain.2005.03.029. PMID 15927394. CS1 maint: Multiple names: authors list (link)
Jump up ^ Raskin J, Pritchett YL, Wang F, et al. (2005). "A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain". Pain Med. 6 (5): 346–56. doi:10.1111/j.1526-4637.2005.00061.x. PMID 16266355.
Jump up ^ Wong MC, Chung JW, Wong TK; Chung; Wong (July 2007). "Effects of treatments for symptoms of painful diabetic neuropathy: systematic review". BMJ. 335 (7610): 87. doi:10.1136/bmj.39213.565972.AE. PMC 1914460  . PMID 17562735. CS1 maint: Multiple names: authors list (link)
Jump up ^ "Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects". Prescrire Int. 15 (85): 168–72. October 2006. PMID 17121211.
Jump up ^ Sultan A, Gaskell H, Derry S, Moore RA; Gaskell; Derry; Moore (2008). "Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials". BMC Neurol. 8: 29. doi:10.1186/1471-2377-8-29. PMC 2529342  . PMID 18673529. CS1 maint: Multiple names: authors list (link)
Jump up ^ Acuna C (October 2008). "Duloxetine for the treatment of fibromyalgia". Drugs Today. 44 (10): 725–34. doi:10.1358/dot.2008.44.10.1269675. PMID 19137126.
Jump up ^ "FDA Approves Cymbalta for the Management of Fibromyalgia". Eli Lilly Co. 2008-06-16. Retrieved 2008-06-17.
Jump up ^ Citrome, L; Weiss-Citrome, A (Jan 2012). "A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?". Postgraduate Medicine. 124 (1): 83–93. doi:10.3810/pgm.2012.01.2521. PMID 22314118.
Jump up ^ Myers, J; Wielage, R. C.; Han, B; Price, K; Gahn, J; Paget, M. A.; Happich, M (2014). "The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: A systematic literature review and meta-analysis". BMC Musculoskeletal Disorders. 15: 76. doi:10.1186/1471-2474-15-76. PMC 4007556  . PMID 24618328.
Jump up ^ "FDA clears Cymbalta to treat chronic musculoskeletal pain". FDA Press Announcements. Food and Drug Administration. 4 November 2010. Retrieved 19 August 2013.
Jump up ^ National Institute for Health and Clinical Excellence. Clinical guideline 40: Urinary incontinence. London, 2006.
Jump up ^ Maund, E; Guski, LS; Gøtzsche, PC (6 February 2017). "Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports". CMAJ : Canadian Medical Association Journal. 189 (5): E194–E203. doi:10.1503/cmaj.151104. PMC 5289870  . PMID 28246265.
Jump up ^ Li J, Yang L, Pu C, Tang Y, Yun H, Han P; Yang; Pu; Tang; Yun; Han (June 2013). "The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis". Int Urol Nephrol. 45 (3): 679–86. doi:10.1007/s11255-013-0410-6. PMID 23504618. CS1 maint: Multiple names: authors list (link)
Jump up ^ "www.uroweb.org" (PDF). Archived from the original (PDF) on 2014-05-04.
Jump up ^ "Urinary incontinence Introduction CG171". Archived from the original on 2014-05-04.
Jump up ^ "Eli Lilly and Company".
Jump up ^ Report a Serious Problem (2013-08-14). "Information for Healthcare Professionals: Duloxetine (marketed as Cymbalta) – Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and 5-Hydroxytryptamine Receptor Agonists (Triptans)". Fda.gov. Retrieved 2013-09-18.
Jump up ^ Cymbalta package insert. Indianapolis, IN: Eli Lilly Pharmaceuticals; 2004, September.
Jump up ^ Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A; Kajdasz; Walker; Raskin; Tylee (May 2006). "Duloxetine 60 mg once daily in the treatment of milder major depressive disorder". Int. J. Clin. Pract. 60 (5): 613–20. doi:10.1111/j.1368-5031.2006.00956.x. PMC 1473178  . PMID 16700869. CS1 maint: Multiple names: authors list (link)
Jump up ^ Chappell; Littlejohn, Kajdasz, Scheinberg, D'Souza, Moldofsky (Jun 2009). "A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia". Clinical Journal of Pain. 25 (5): 365–375. doi:10.1097/ajp.0b013e31819be587. PMID 19454869. CS1 maint: Multiple names: authors list (link)
Jump up ^ Duenas, H; Brnabic, Lee, Montejo, Prakash, Casimiro-Querubin, Khaled, Dossenbach, Raskin (Nov 2011). "Treatment-emergent sexual dysfunction with SSRIs and duloxetine: efferctiveness and functional outcomes over a 6-month observational period". International Journal of Psychiatry in Clinical Practice. 15 (4): 242–254. doi:10.3109/13651501.2011.590209. PMID 22121997. CS1 maint: Multiple names: authors list (link)
^ Jump up to: a b Clayton, A; Kornstein, Prakash, Mallinckrodt, Wohlreich (July 2007). "Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder". Journal of Sexual Medicine. 4 (4 Pt 1): 917–929. doi:10.1111/j.1743-6109.2007.00520.x. PMID 17627739. CS1 maint: Multiple names: authors list (link)
Jump up ^ Perahia DG, Kajdasz DK, Desaiah D, Haddad PM; Kajdasz; Desaiah; Haddad (December 2005). "Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder". J Affect Disord. 89 (1–3): 207–12. doi:10.1016/j.jad.2005.09.003. PMID 16266753. CS1 maint: Multiple names: authors list (link)
Jump up ^ Levenson M, Holland C. "Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". Retrieved 2007-05-13.
Jump up ^ Stone MB, Jones ML (2006-11-17). "Clinical review: relationship between antidepressant drugs and suicidality in adults" (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA. pp. 11–74. Retrieved 2007-09-22.
Jump up ^ Levenson M, Holland C (2006-11-17). "Statistical Evaluation of Suicidality in Adults Treated with Antidepressants" (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA. pp. 75–140. Retrieved 2007-09-22.
Jump up ^ "Historical Information on Duloxetine hydrochloride (marketed as Cymbalta)".
Jump up ^ [1] Duloxetine Side Effects, and Drug Interactions – RxList Monographs
Jump up ^ Bymaster, FP; Dreshfield-Ahmad, LJ; Threlkeld, PG; Shaw, JL; Thompson, L; Nelson, DL; Hemrick-Luecke, SK; Wong, DT (December 2001). "Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors". Neuropsychopharmacology. 25 (6): 871–80. doi:10.1016/S0893-133X(01)00298-6. PMID 11750180.
Jump up ^ Stahl, S. (2013). Stahl's essential pharmacology, 4th ed. Cambridge University Press, New York. p. 305, 308, 309.
Jump up ^ Stahl, SM; Grady, Moret, Briley (Sep 2005). "SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants". CNS Spectrums. 10 (9): 732–747. PMID 16142213. CS1 maint: Multiple names: authors list (link)
^ Jump up to: a b Bymaster, FP; Lee, Knadler (2005). "The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression". Curr Pharm Des. 11 (12): 1475–93. doi:10.2174/1381612053764805. PMID 15892657.
Jump up ^ De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M; Conti; Serroni; Moschetta; Olivieri; Carano; Salerno; Cavuto; Farina; Alessandrini; Janiri; Pozzi; Di Giannantonio (2010). "The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature". Int J Immunopathol Pharmacol. 23 (2): 417–22. PMID 20646337. CS1 maint: Multiple names: authors list (link)
Jump up ^ Wang SY, Calderon J, Kuo Wang G; Calderon; Kuo Wang (September 2010). "Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner". Anesthesiology. 113 (3): 655–65. doi:10.1097/ALN.0b013e3181e89a93. PMID 20693878. CS1 maint: Multiple names: authors list (link)
^ Jump up to: a b c "Cymbalta product insert" (PDF).
Jump up ^ Robertson DW, Wong DT, Krushinski JH (1990-09-11). "United States Patent 4,956,388: 3-Aryloxy-3-substituted propanamines". USPTO. Retrieved 2008-05-17.
Jump up ^ Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR; Robertson; Bymaster; Krushinski; Reid (1988). "LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug". Life Sci. 43 (24): 2049–57. doi:10.1016/0024-3205(88)90579-6. PMID 2850421. CS1 maint: Multiple names: authors list (link)
Jump up ^ Bymaster FP, Beedle EE, Findlay J, et al. (December 2003). "Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake". Bioorg. Med. Chem. Lett. 13 (24): 4477–80. doi:10.1016/j.bmcl.2003.08.079. PMID 14643350.
Jump up ^ "Approval package for: application number NDA 721-427. Administrative/Correspondence #2" (PDF). The FDA Center for Drug Evaluation and Research. 2003. Retrieved 2008-05-18. [dead link]
Jump up ^ FDA news
Jump up ^ "Summary Basis of Decision (SBD): Cymbalta". Health Canada. 2008-05-05.
Jump up ^ Steyer R (2006-02-15). "Lilly Won't Pursue Yentreve for U.S." TheStreet.com. Archived from the original on 2009-02-02. Retrieved 2008-05-18.
Jump up ^ Lenzer J (2005). "FDA warns that antidepressants may increase suicidality in adults". BMJ. 331 (7508): 70. doi:10.1136/bmj.331.7508.70-b. PMC 558648  . PMID 16002878.
Jump up ^ "FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder". News-Medical. February 26, 2007. Retrieved 25 December 2013.
Jump up ^ Staton, Tracy (July 9, 2012). "Lilly could net $1.5B-plus from Cymbalta extension". FiercePharma. Retrieved 25 December 2013.
Jump up ^ Palmer, Eric (April 11, 2013). "Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliff". FiercePharma. Retrieved 25 December 2013.
Jump up ^ Hrenchir, Tim (2 September 2015). "10 Most-Prescribed Antidepressant Medications". Newsmax.
Jump up ^ Anson, Pat (December 12, 2013). "Generic Cheaper Versions of Cymbalta Approved". National Pain Report. Retrieved January 2, 2014.
External links[edit]
Eli Lilly Cymbalta Prescribing Guide
U.S. National Library of Medicine: Drug Information Portal – Duloxetine
[show]
v
t
e
Antidepressants (N06A)
[hide]
Specific reuptake inhibitors and/or receptor modulators
SSRIs
Citalopram
Escitalopram
Fluoxetine#
Fluvoxamine
Indalpine‡
Paroxetine
Sertraline
Zimelidine‡
SNRIs
Desvenlafaxine
Duloxetine
Levomilnacipran
Milnacipran
Tofenacin
Venlafaxine
NRIs
Atomoxetine
Reboxetine
Viloxazine
NDRIs
Amineptine‡
Bupropion
Nomifensine‡
NaSSAs
Mianserin
Mirtazapine
Setiptiline
SARIs
Etoperidone
Nefazodone
Trazodone
SMS
Vilazodone
Vortioxetine
Others
Agomelatine
Amisulpride
Esketamine†
Etryptamine‡
Indeloxazine
flupentixol
Ketamine†
Medifoxamine‡
Metryptamine‡
Oxaflozane‡
Pivagabine‡
Tandospirone
Teniloxazine
Tianeptine
[hide]
Tricyclic and tetracyclic antidepressants
TCAs
Amineptine‡
Amitriptyline#
Amitriptylinoxide
Butriptyline‡
Clomipramine#
Demexiptiline‡
Desipramine
Dibenzepin
Dimetacrine‡
Dosulepin
Doxepin
Imipramine
Imipraminoxide‡
Iprindole‡
Lofepramine
Melitracen
Metapramine‡
Nitroxazepine
Nortriptyline
Noxiptiline
Opipramol
Pipofezine
Propizepine‡
Protriptyline
Quinupramine‡
Tianeptine
Trimipramine
TeCAs
Amoxapine
Maprotiline
Mianserin
Mirtazapine
Setiptiline
Others
Tiazesim
[hide]
Monoamine oxidase inhibitors
Non-selective
Irreversible: Benmoxin‡
Iproclozide‡
Iproniazid‡
Isocarboxazid
Isoniazid#
Linezolid#
Mebanazine‡
Nialamide‡
Octamoxin‡
Phenelzine
Pheniprazine‡
Phenoxypropazine‡
Pivhydrazine‡
Safrazine‡
Tedizolid
Tranylcypromine
Reversible: Caroxazone‡
Mixed: Bifemelane
MAOA-selective
Reversible: Eprobemide
Metralindole
Minaprine‡
Moclobemide
Pirlindole
Tetrindole
Toloxatone
MAOB-selective
Irreversible: Selegiline
[hide]
Adjunctive therapies
Atypical antipsychotics (aripiprazole, brexpiprazole, lurasidone, olanzapine, quetiapine, risperidone)
Buspirone
Lithium (lithium carbonate, lithium citrate)
Thyroid hormones (triiodothyronine (T3), levothyroxine (T4))
[hide]
Miscellaneous
Ademetionine (SAMe)
Hypericum perforatum (St. John's Wort)
Oxitriptan (5-HTP)
Rubidium chloride (RbCl)
Tryptophan
#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III
[show]
v
t
e
Neuropathic pain and fibromyalgia pharmacotherapies
Monoaminergics
SNRIs (e.g., duloxetine, milnacipran)
TCAs (e.g., amitriptyline, nortriptyline, dosulepin)
Opioid MRIs (e.g., tapentadol, tramadol)
Ion channel blockers
Anticonvulsants (e.g., gabapentin, pregabalin, carbamazepine, oxcarbazepine, lacosamide, lamotrigine)
Local anesthetics (e.g., lidocaine)
Mexiletine
TCAs (e.g., amitriptyline, nortriptyline, desipramine)
Ziconotide
Others
Alpha lipoic acid
Benfotiamine
Botulinum toxin A
Bupropion
Cannabinoids (e.g., cannabis, dronabinol, nabilone)
NMDA receptor antagonists (e.g., ketamine, dextromethorphan, methadone)
Opioids (e.g., hydrocodone, morphine, oxycodone, methadone, buprenorphine, tramadol, tapentadol)
Sodium oxybate (GHB)
[show]
v
t
e
Monoamine reuptake inhibitors
DAT
(DRIs)
Piperazines: DBL-583
GBR-12783
GBR-12935
GBR-13069
GBR-13098
Nefazodone
Vanoxerine
Piperidines: 4-Fluoropethidine
Benocyclidine (BTCP)
Desoxypipradrol
Dexmethylphenidate
Difemetorex
Ethylphenidate
HDMP-28
Methylphenidate
Pethidine (meperidine)
Phencyclidine
Pipradrol
Tenocyclidine
Pyrrolidines: Diphenylprolinol
MDPV
Naphyrone
Prolintane
Pyrovalerone
Tropanes: Altropane
Benzatropine (benztropine)
Brasofensine
CFT
Cocaine
Dichloropane
Difluoropine
Etybenzatropine (ethybenztropine)
FE-β-CPPIT
FP-β-CPPIT
Ioflupane (123I)
RTI-55
RTI-112
RTI-113
RTI-121
RTI-126
RTI-150
RTI-177
RTI-229
RTI-336
Tesofensine
Troparil
Tropoxane
WF-11
WF-23
WF-31
WF-33
Others: Adrafinil
Amifitadine
Armodafinil
Amfonelic acid
Amineptine
Ansofaxine
BTQ
BTS 74,398
Bupropion
Chaenomeles speciosa
Ciclazindol
Dasotraline
Desmethylsertraline
Desmethylsibutramine
Diclofensine
Didesmethylsibutramine
Dimethocaine
Diphenylpyraline
Dizocilpine (MK-801)
DOV-102,677
DOV-216,303
Efavirenz
Ephenidine
Esketamine
EXP-561
Fencamfamin
Fezolamine
Fluorenol
GYKI-52895
Indatraline
Ketamine
Lefetamine
Levophacetoperane
Liafensine
LR-5182
Manifaxine
Mazindol
Medifoxamine
Mesocarb
Metaphit
MIN-117 (WF-516)
Modafinil
Nefopam
Nomifensine
NS-2359
O-2172
Oroxylin A
Perafensine
Pridefine
Radafaxine
Rimcazole
Sertraline
Sibutramine
Solriamfetol
Tametraline
Tedatioxetine
Tripelennamine
Venlafaxine
NET
(NRIs)
Selective norepinephrine reuptake inhibitors: Amedalin
Alseroxylon
Ciclazindol
Daledalin
Edivoxetine
Esreboxetine
Lortalamine
Mazindol
Nisoxetine
Reboxetine
Talopram
Talsupram
Tandamine
Teniloxazine
Viloxazine
Norepinephrine–dopamine reuptake inhibitors: Amineptine
Bupropion
Fencamine
Fencamfamin
Hydroxybupropion
Lefetamine
Levophacetoperane
LR-5182
Manifaxine
Methylphenidate
Nomifensine
O-2172
Radafaxine
Solriamfetol
Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
BTS-54505
CP-39,332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN-5652
Milnacipran
N-Methyl-PPPA
Nafenodone
PPPA
Tofenacin
Venlafaxine
WY-45233
Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine
Diclofensine
Didesmethylsibutramine
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)
Tricyclic antidepressants: Amitriptyline
Butriptyline
Cianopramine
Clomipramine
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Melitracen
Nortriptyline
Protriptyline
Trimipramine
Tetracyclic antidepressants: Amoxapine
Maprotiline
Mianserin
Oxaprotiline
Setiptiline
Others: Antihistamines (e.g., brompheniramine, chlorphenamine, pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., ketamine, phencyclidine)
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g., desmetramadol, methadone, pethidine (meperidine), tapentadol, tramadol, levorphanol)
SERT
(SRIs)
Selective serotonin reuptake inhibitors: Alaproclate
Centpropazine
Cericlamine
Citalopram
Dapoxetine
Desmethylcitalopram
Didesmethylcitalopram
Escitalopram
Femoxetine
Fluoxetine
Fluvoxamine
Indalpine
Ifoxetine
Norfluoxetine
Omiloxetine
Panuramine
Paroxetine
PIM-35
Pirandamine
RTI-353
Seproxetine
Sertraline
Zimelidine
Selective serotonin reuptake inhibitors and serotonin receptor modulators: Etoperidone
Litoxetine
Lubazodone
LY-393558
SB-649915
TGBA01AD
Trazodone
Vilazodone
Vortioxetine
Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
Bicifadine
BTS-54505
CP-39332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN-5652
Milnacipran
N-Methyl-PPPA
PPPA
Tofenacin
Venlafaxine
WY-45233
Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine
Diclofensine
Didesmethylsibutramine
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)
Tricyclic antidepressants: Amitriptyline
Cianopramine
Clomipramine
Cyanodothiepin
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Nortriptyline
Pipofezine
Protriptyline
Others: A-80426
Amoxapine
Antihistamines (e.g., brompheniramine, chlorphenamine, dimenhydrinate, diphenhydramine, mepyramine (pyrilamine), pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., 3-MeO-PCP, esketamine, ketamine, methoxetamine, phencyclidine)
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g., dextropropoxyphene, methadone, pethidine (meperidine), levorphanol, tapentadol, tramadol)
Roxindole
VMATs
Amiodarone
Amphetamines (e.g., amphetamine, methamphetamine, MDMA)
APP
AZIK
Bietaserpine
Deserpidine
Deutetrabenazine
Dihydrotetrabenazine
Efavirenz
GBR-12935
GZ-793A
Ibogaine
Ketanserin
Lobeline
Methoxytetrabenazine
Reserpine
Rose bengal
Tetrabenazine
Valbenazine
Vanoxerine (GBR-12909)
Others
DAT enhancers: Luteolin
DAT modulators: Agonist-like: SoRI-9804
SoRI-20040; Antagonist-like: SoRI-20041
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Retrieved from "https://en.wikipedia.org/w/index.php?title=Duloxetine&oldid=841513454"
Categories:
Serotonin-norepinephrine reuptake inhibitors
Eli Lilly and Company
Thiophenes
Naphthol ethers
Amines
Hidden categories:
CS1 German-language sources (de)
All articles with dead external links
Articles with dead external links from November 2010
CS1 maint: Multiple names: authors list
Articles with dead external links from June 2016
Template:drugs.com link with non-standard subpage
Articles with changed CASNo identifier
Articles with changed FDA identifier
ECHA InfoCard ID from Wikidata
Multiple chemicals in Infobox drug
Chemicals using indexlabels
Chemical articles with multiple CAS registry numbers
Drug has EMA link
Drugboxes which contain changes to verified fields
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
تۆرکجه
Dansk
Deutsch
Español
فارسی
Français
한국어
Italiano
עברית
Magyar
Македонски
Nederlands
日本語
Polski
Português
Русский
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
中文
12 more
Edit links
This page was last edited on 16 May 2018, at 09:13.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

value: a

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

attrs: href title

attrs: role class

values:
note
hatnote navigation-not-searchable

values: International nonproprietary name (INN): Duloxetine

value: caption

value: img

attrs: href class

value: td

attrs: colspan style

value: tr

value: th

values: American Society of Health-System Pharmacists

values:
/wiki/U.S._Food_and_Drug_Administration
mw-redirect
U.S. Food and Drug Administration

values: Anatomical Therapeutic Chemical Classification System

values: Standard for the Uniform Scheduling of Drugs and Poisons

values: font-size: 105%; background: transparent; text-align: left;

values: list-style: none none; margin-left: 0px; word-break: break-all; text-align: left; padding-left: 1.5em; text-indent: -1.5em; font-size: 105%; margin-top: 0px; margin-bottom: 0px; line-height: inherit; display: none;

values:
NavFrame collapsed
border: none; padding: 0;
NavFrame1

values:
nofollow
external text
https://www.drugbank.ca/drugs/DB00476

values:
nofollow
external text
http://www.kegg.jp/entry/D07880

values:
/wiki/ECHA_InfoCard
mw-redirect
ECHA InfoCard

attrs: alt src width height style srcset data-file-width data-file-height

values: chemapps.stolaf.edu (3D interactive model)

values: Simplified molecular-input line-entry system

values: word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;

values: list-style: none none; margin-left: 0px; word-break: break-all; font-size: 105%; margin-top: 0px; margin-bottom: 0px; line-height: inherit; display: none;

values:
NavFrame collapsed
border: none; padding: 0;
NavFrame2

values:
NavFrame collapsed
border: none; padding: 0;
NavFrame3

values:
/wiki/Musculoskeletal_pain
mw-redirect
Musculoskeletal pain

values: American Association for Neurology (page does not exist)

values: European Federation of Neurological Societies

values: Edit section: Generalized anxiety disorder

values: Canadian Psychiatric Association (page does not exist)

values: Edit section: Diabetic peripheral neuropathy

values:
/wiki/Serum_glucose
mw-redirect
Serum glucose

values:
/wiki/BMC_Neurology
mw-redirect
BMC Neurology

values: Edit section: Fibromyalgia and chronic pain

values: Edit section: Stress urinary incontinence

values:
/wiki/Clinical_trials
mw-redirect
Clinical trials

values:
/wiki/Side_effects
mw-redirect
Side effects

values:
/wiki/SSRI_discontinuation_syndrome
mw-redirect
SSRI discontinuation syndrome

values:
/wiki/Labile_affect
mw-redirect
Labile affect

values:
/wiki/Black_box_warning
mw-redirect
Black box warning

values:
/wiki/Statistically_significant
mw-redirect
Statistically significant

values:
/wiki/Alanine_aminotransferase
mw-redirect
Alanine aminotransferase

values:
/wiki/Angioneurotic_edema
mw-redirect
Angioneurotic edema

values:
/wiki/Aspartate_aminotransferase
mw-redirect
Aspartate aminotransferase

values:
/wiki/Elimination_half-life
mw-redirect
Elimination half-life

attrs: alt src width height class srcset data-file-width data-file-height

values:
/wiki/Good_Manufacturing_Practice
mw-redirect
Good Manufacturing Practice

values: National Institute for Health and Clinical Excellence

values:
nofollow
external text
https://www.nice.org.uk/guidance/CG96

attrs: alt src title width height srcset data-file-width data-file-height

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21482920

values:
nofollow
external text
//doi.org/10.1200%2FJCO.2013.54.0914

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24733808

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22760463

values:
nofollow
external text
//doi.org/10.1002%2Fmus.22092

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21484835

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20402746

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24385423

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25121155

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23076926

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19480470

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16933543

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24297210

values:
nofollow
external text
//doi.org/10.1016%2Fj.pain.2005.03.029

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15927394

values: Category:CS1 maint: Multiple names: authors list

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16266355

values:
nofollow
external text
//doi.org/10.1136%2Fbmj.39213.565972.AE

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17562735

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17121211

values:
nofollow
external text
//doi.org/10.1186%2F1471-2377-8-29

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18673529

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19137126

values:
nofollow
external text
//doi.org/10.3810%2Fpgm.2012.01.2521

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22314118

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24618328

values:
nofollow
external text
https://www.nice.org.uk/guidance/CG40

values:
nofollow
external text
//doi.org/10.1503%2Fcmaj.151104

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/28246265

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23504618

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16700869

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19454869

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22121997

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17627739

values:
nofollow
external text
//doi.org/10.1016%2Fj.jad.2005.09.003

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16266753

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11750180

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16142213

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15892657

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20646337

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20693878

values:
nofollow
external text
http://pi.lilly.com/us/cymbalta-pi.pdf

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2850421

values:
nofollow
external text
//doi.org/10.1016%2Fj.bmcl.2003.08.079

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14643350

values:
nofollow
external text
//doi.org/10.1136%2Fbmj.331.7508.70-b

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16002878

values:
nofollow
external text
http://www.news-medical.net/?id=22194

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;

values: Noradrenergic and specific serotonergic antidepressants

values: Serotonin antagonist and reuptake inhibitors

values: nowraplinks collapsible uncollapsed navbox-subgroup

values:
/wiki/Tricyclic_antidepressants
mw-redirect
Tricyclic antidepressants

values:
/wiki/Tetracyclic_antidepressants
mw-redirect
Tetracyclic antidepressants

values:
/wiki/Thyroid_hormone
mw-redirect
Thyroid hormone

values: nowraplinks collapsible collapsed navbox-inner

values: Template:Neuropathic pain and fibromyalgia pharmacotherapies

values: Template talk:Neuropathic pain and fibromyalgia pharmacotherapies

values:
/wiki/Pharmaceutical_drug
mw-redirect
Pharmaceutical drug

values:
/wiki/Monoamine_reuptake_inhibitors
mw-redirect
Monoamine reuptake inhibitors

values:
/wiki/Ion_channel_blocker
mw-redirect
Ion channel blocker

values:
/wiki/Alpha_lipoic_acid
mw-redirect
Alpha lipoic acid

values:
/wiki/Botulinum_toxin_A
mw-redirect
Botulinum toxin A

values: nowraplinks collapsible autocollapse navbox-inner

values: Template talk:Monoamine reuptake inhibitors

values:
/wiki/Dopamine_reuptake_inhibitors
mw-redirect
Dopamine reuptake inhibitors

values: Desmethylsibutramine (page does not exist)

values: Didesmethylsibutramine (page does not exist)

values:
/wiki/Histamine_antagonist
mw-redirect
Histamine antagonist

values:
/wiki/Serotonin_reuptake_inhibitors
mw-redirect
Serotonin reuptake inhibitors

values:
/wiki/Vesicular_monoamine_transporters
mw-redirect
Vesicular monoamine transporters

values: 3-Amino-2-phenylpropene (page does not exist)

values: 7-Azido-8-iodoketanserin (page does not exist)

values: Methoxytetrabenazine (page does not exist)

values: Category:CS1 German-language sources (de)

values: Category:All articles with dead external links

values: Category:Articles with dead external links from November 2010

values: Category:Articles with dead external links from June 2016

values: Category:Template:drugs.com link with non-standard subpage

values: Category:Articles with changed CASNo identifier

values: Category:Articles with changed FDA identifier

values: Category:Multiple chemicals in Infobox drug

values: Category:Chemical articles with multiple CAS registry numbers

values: Category:Drugboxes which contain changes to verified fields

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Duloxetine
View the content page [ctrl-alt-c]
c

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values:
/wiki/Wikipedia:File_Upload_Wizard
Upload files [ctrl-alt-u]
u

values: A list of all special pages [ctrl-alt-q]

values: Permanent link to this revision of the page

values: Link to connected data repository item [ctrl-alt-g]

values: Printable version of this page [ctrl-alt-p]

values:
interlanguage-link interwiki-azb
display: none;

values:
https://da.wikipedia.org/wiki/Duloxetin
Duloxetin – Danish
da
da
interlanguage-link-target

values:
interlanguage-link interwiki-da
display: none;

values:
https://de.wikipedia.org/wiki/Duloxetin
Duloxetin – German
de
de
interlanguage-link-target

values: دولوکستین – Persian

values:
interlanguage-link interwiki-fa
display: none;

values: דולוקסטין – Hebrew

values:
interlanguage-link interwiki-he
display: none;

values:
https://hu.wikipedia.org/wiki/Duloxetin
Duloxetin – Hungarian
hu
hu
interlanguage-link-target

values:
interlanguage-link interwiki-hu
display: none;

values: Дулоксетин – Macedonian

values:
interlanguage-link interwiki-mk
display: none;

values:
interlanguage-link interwiki-nl
display: none;

values: デュロキセチン – Japanese

values:
interlanguage-link interwiki-pl
display: none;

values: Дулоксетин – Russian

values:
interlanguage-link interwiki-sr
display: none;

values:
interlanguage-link interwiki-sh
display: none;

values:
interlanguage-link interwiki-fi
display: none;

values:
https://sv.wikipedia.org/wiki/Duloxetin
Duloxetin – Swedish
sv
sv
interlanguage-link-target

values:
interlanguage-link interwiki-sv
display: none;

values: All languages (initial selection from common choices by you and others)

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Duloxetine rootpage-Duloxetine skin-vector action-view